Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec

Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec

Bibliographic Details
Main Authors:	Jamie Lebhar, BME, Jennifer Jacobs, BS, Khushnood Faraz, BS, April K.S. Salama, MD, Paul J. Mosca, MD, PhD, MBA
Format:	Article
Language:	English
Published:	Elsevier 2023-10-01
Series:	JAAD Case Reports
Subjects:	intralesional in-transit liver transplant squamous cell carcinoma talimogene Laherparepvec T-VEC
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352512623002849

Similar Items

Durable melanoma control following disseminated talimogene laherparepvec herpetic infection
by: Leonid Shmuylovich, MD, PhD, et al.
Published: (2022-11-01)

Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report
by: Saurabh D. Chitnis, et al.
Published: (2024-05-01)

Locoregional melanoma metastases resistant to PD-1 inhibitor therapy treated with intralesional talimogene laherparepvec
by: Matthew M. Wallace, MD, et al.
Published: (2024-01-01)

A Novel Intersection: Cytomegalovirus Gastritis Following Cemiplimab and Talimogene Laherparepvec in a Patient With Advanced Cutaneous Squamous Cell Carcinoma
by: Goar Egoryan, et al.
Published: (2024-12-01)

Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report
by: Anne Fröhlich, et al.
Published: (2020-05-01)

Multimodal Therapy Approaches for NUT Carcinoma by Dual Combination of Oncolytic Virus <i>Talimogene Laherparepvec</i> with Small Molecule Inhibitors
by: Stavros Sotiriadis, et al.
Published: (2024-05-01)

Use of Talimogene Laherparepvec to Treat Cutaneous Squamous Cell Carcinoma in a Renal Transplant Patient
by: Max Miller, et al.
Published: (2023-06-01)

Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition
by: Zoë Blake, et al.
Published: (2018-04-01)

Inflammatory Colitis after Treatment of Melanoma with Talimogene Laherparepvec (T-VEC)
by: Jennifer Gardner, et al.
Published: (2018-07-01)

Safety of talimogene laherparepvec: a real‐world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)
by: Yifan Hong, et al.
Published: (2024-12-01)

Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec
by: Jonathan T. Blackmon, et al.
Published: (2017-07-01)

Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases
by: Jonathan T. Blackmon, et al.
Published: (2017-05-01)

Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient
by: Kelsey E. Hirotsu, MD, et al.
Published: (2021-07-01)

Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)
by: Sant P. Chawla, et al.
Published: (2023-05-01)

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
by: Robert H. I. Andtbacka, et al.
Published: (2019-06-01)

Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells
by: Jens Tijtgat, et al.
Published: (2021-10-01)

Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2)
by: James Sun, et al.
Published: (2020-07-01)

Talimogene laherparepvec: First in class oncolytic virotherapy
by: Robert M. Conry, et al.
Published: (2018-04-01)

Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab
by: David M. Miller, et al.
Published: (2018-11-01)

A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors
by: Lucas Moreno, et al.
Published: (2023-05-01)

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
by: Howard L. Kaufman, et al.
Published: (2017-09-01)

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial
by: Maartje W. Rohaan, et al.
Published: (2022-08-01)

Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus H-1
by: Markus eMoehler, et al.
Published: (2014-05-01)

Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials
by: Ibrahim Ragab Eissa, et al.
Published: (2017-07-01)

Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study
by: Kleemann J, et al.
Published: (2021-07-01)

Clitoral metastasis of vulvar melanoma treated with talimogene laherparepvec
by: Erin M. McClure, BS, et al.
Published: (2023-02-01)

Resolution of metastatic neck nodes associated with a periauricular cutaneous squamous cell carcinoma after intranodal injection of talimogene laherparepvec
by: Yonglu Che, MD, PhD, et al.
Published: (2024-04-01)

Diffuse eruptive squamous atypia, also known as eruptive keratoacanthoma: Unique case presentation
by: Julia Griffin, BS, et al.
Published: (2024-07-01)

Successful treatment of squamous cell carcinoma with intralesional methotrexate
by: L.G. Vega-González, MD, et al.
Published: (2022-06-01)

Complete resolution of PD-1 refractory, locoregionally advanced Merkel cell carcinoma with talimogene laherparepvec
by: Neha Singh, BS, et al.
Published: (2023-06-01)

Four cases of disseminated herpes simplex virus following talimogene laherparepvec injections for unresectable metastatic melanoma
by: Kate E. Beekman, BS, et al.
Published: (2023-03-01)

Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class
by: Howard L. Kaufman, et al.
Published: (2022-02-01)

Innovative Therapeutic Approaches in Primary Cutaneous B Cell Lymphoma
by: Claudia C. V. Lang, et al.
Published: (2020-08-01)

Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy
by: Jason M. Rizzo, MD, PhD, et al.
Published: (2018-05-01)

Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment
by: Jennifer Gardner, et al.
Published: (2022-10-01)

Efficacy and Safety of Intralesional Methotrexate in the Treatment of a Large Keratoacanthoma of the Dorsal Hand in a 99-Year-Old Woman
by: Valentina Della Valle, et al.
Published: (2018-11-01)

Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma
by: Umang Swami, et al.
Published: (2019-01-01)

Skin cancers arising within tattoos: A systematic reviewCapsule Summary
by: Jamie Lebhar, BME, et al.
Published: (2024-09-01)

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
by: Ann W. Silk, et al.
Published: (2016-09-01)

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanomaResearch in context
by: Robert H.I. Andtbacka, et al.
Published: (2019-09-01)